Advertisement

Product › Details
RNActive® vaccination technology
![]() |
Next higher product group | RNAi technology_o |
![]() |
Status | 2006-01-18 development existent |
![]() |
Organisation | CureVac GmbH |
Today | CureVac AG | |
Record changed: 2018-02-01 |
Advertisement
![Picture [iito] Plain Stupid Simple 650x80px](/banner/iito-business-intelligence-20200507-650-080-summer-banner-series-plain-stupid-simple.jpg)
More documents for RNActive® vaccination technology
- [1] CureVac AG. (1/24/18). "Press Release: CureVac Expands Intellectual Property Position that Significantly Improves Protein Expression for its mRNA-Based Vaccines and Therapeutics". Tübingen....
- [2] CureVac AG. (10/23/17). "Press Release: Publication in npj Vaccines Demonstrates CureVac’s RNActive Vaccine Is Superior to Licensed Vaccines". Tübingen & Boston, MA....
- [3] CureVac AG. (10/18/17). "Press Release: Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines". Indianapolis, IN & Tübingen....
- [4] CureVac AG. (7/20/17). "Press Release: CureVac to Receive Patent Claiming the Combination of mRNA Vaccines with Anti-PD-1 Antibodies". Tübingen....
- [5] CureVac AG. (6/26/17). "Press Release: CureVac Expands GMP Production Capacities for RNA Products". Tübingen....
- [6] CureVac AG. (6/13/17). "Press Release: CureVac Extends Global Intellectual Property Estate for Prophylactic mRNA Vaccines". Tübingen....
- [7] CureVac AG. (5/2/17). "Press Release: CureVac Appoints Daniel Menichella as CEO of CureVac Inc., the Company’s US Subsidiary". Tübingen....
- [8] CureVac AG. (11/8/16). "Press Release: CureVac Secures an Additional $29.5 Million From Two New Investors". Tübingen....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top